Lymphoma News and Research

RSS

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

Simple blood test can better identify patients at risk of relapse for B-cell lymphoma

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma, a cancer that begins in certain immune system cells and can occur almost anywhere in the body. More than 28,000 people are diagnosed with DLBCL each year.

21 Oct 2019

Creatine serves as a molecular battery to power killer T cells' fight against cancer

Creatine, the organic acid that is popularly taken as a supplement by athletes and bodybuilders, serves as a molecular battery for immune cells by storing and distributing energy to power their fight against cancer, according to new UCLA research.

18 Oct 2019

Scientists harness the power of immune system to test novel cancer treatment

The field of immunotherapy has revolutionized the way people with incurable cancers are treated, saving the lives of many people whose disease would have otherwise been seen as a death sentence. Despite its success in treating people with deadly forms of leukemia and lymphoma, there are still many people who do not benefit from the treatment or eventually experience a relapse of their cancer.

16 Oct 2019

Drug-light combination could offer better control over CAR T-cell treatments

Bioengineers at the University of California San Diego are a step closer to making CAR T-cell therapy safer, more precise and easy to control.

15 Oct 2019

Study may lead the way to decrease DLBCL relapse, development of second primary cancer

With improved treatments, especially the use of anti-cancer immunotherapies, more than two-thirds of all patients diagnosed with diffuse large B-cell lymphoma (DLBCL) will survive. However, after treatment, patients are at a small but real risk of developing a new cancer, called a second primary cancer.

8 Oct 2019

HIV-1 Tat expression leads to perturbations in cellular protein expression, research suggests

The cover for issue 54 of Oncotarget features Figure 2, "Comparative proteomic profiling of the peptides/proteins identified from 293T, IL16lamp2b and mExo-Tat samples," by Lu, et al.

4 Oct 2019

NUS researcher invents novel transfection technique to deliver DNA into immune cells

Immunotherapy is a promising cancer treatment that uses genetically modified immune cells to fight cancer. It can be used as a primary treatment or in combination with other treatments such as radiation and chemotherapy to slow down or stop the growth of cancer cells and prevent them from spreading to other parts of the body.

4 Oct 2019

Researcher aims to make CRISPR-Cas9 system safer and more precise

The mere mention of gene editing and DNA altering might conjure up images of designer babies, but that is not what researcher Jin Liu has in mind.

26 Sep 2019

Tasmanian devil study may give clues to how cancers evade the immune system

A cluster of interacting proteins that are active in both human cancers and Tasmanian devil facial tumors, may give clues to how cancers evade the immune system, according to a study part-funded by Cancer Research UK and published in Cancer Cell today.

26 Sep 2019

BCG vaccination in childhood could decrease risk of lung cancer

A common tuberculosis vaccine could decrease the risk of lung cancer if administered during early childhood, according to a study published Sept. 25 in JAMA Network Online.

25 Sep 2019

Newly synthesized anticancer compound can block cancer signaling mechanism

Of the various different functions that proteins perform in a cell, a crucial one is the recognition and transmission of certain "signals," collectively referred to as signal transduction.

24 Sep 2019

Study provides new insight into how cells maintain their identity

In the body's cells, some proteins are of vital importance as to which genes are active or turned off. Now, researchers from the University of Copenhagen and the Memorial Sloan Kettering Cancer Center have discovered which proteins are necessary in order to maintain the proper genetic regulation.

20 Sep 2019

Study uncovers new factor in the development of childhood lymphoma

A study recently published in the renowned journal Blood, led by Kaan Boztug, Scientific Director of the St. Anna Children's Cancer Research Institute, the Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases, Adjunct Principal Investigator at the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences and Associate Professor at the Medical University of Vienna, together with scientists from Israel, Germany, Turkey, Colombia, Argentina and the USA, investigated four patients from independent families with malignancy, autoimmunity and immunodeficiency.

19 Sep 2019

Study examines racial disparities in survival outcomes of pediatric patients with Hodgkin lymphoma

In what is believed to be the largest dataset study to date examining the role of race on survival outcome for pediatric patients with Hodgkin lymphoma, investigators at Rutgers Cancer Institute of New Jersey have found that black patients have significantly worse overall survival at five years than white patients when accounting for all available clinical variables.

18 Sep 2019

Patients with non-Hodgkin's lymphoma may benefit from radiation, experience reduced side effects

Treating non-Hodgkin's lymphoma patients with radiation therapy as an additional treatment while they wait for their CAR T cells to be manufactured may reduce the risk of CAR T therapy side effects once it is administered, according to a new study from researchers in the Abramson Cancer Center at the University of Pennsylvania.

18 Sep 2019

New method developed to address failures in promising anti-cancer drug

Biomedical engineers at Duke University have developed a method to address failures in a promising anti-cancer drug, bringing together tools from genome engineering, protein engineering and biomaterials science to improve the efficacy, accuracy and longevity of certain cancer therapies.

17 Sep 2019

Scientists use CAR-T cells to reverse cardiac fibrosis

Scientists have used CAR-T cell therapy to treat cardiac fibrosis, a key part of heart disease and cardiac arrest.

12 Sep 2019

CAR T-cell therapy may be viable treatment option for heart disease

CAR T-cell therapy, a rapidly emerging form of immunotherapy using patients' own cells to treat certain types of cancers, may be a viable treatment option for another life-threatening condition: heart disease.

12 Sep 2019

Mutations linked with sensitivity or resistance to immunotherapy in mNSCLC

The relationship between gene alterations and response to anti-PD-L1 with and without anti-CTLA-4 are not well characterized.

10 Sep 2019

Scientists reveal the structure of a key protein in Epstein-Barr virus infection

Scientists at the Institute for Research in Biomedicine and the Molecular Biology Institute of Barcelona have published a study in the journal Nature Communications revealing the structure of a key protein, known as a portal, in Epstein-Barr virus infection.

29 Aug 2019